Press Releases

Click here to join our email distribution list.

Results from phase 2b “DEEP” study in severe pre-eclampsia
22 April 2008
London, UK; Brentwood, TN, US; 22 April 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that its placebo-controlled phase 2b Digoxin Immune Fab (DIF) Efficacy Evaluation in Pre-eclampsia (“DEEP”) study in severe pre-eclampsia has met one of its two primary endpoints. Severe pre-eclampsia is a potentially life threatening complication of pregnancy for which there is no effective treatment other than delivery of the baby. Pre-eclampsia is a leading cause of maternal and infant death throughout the world.
More Information

Interim Management Statement
14 February 2008
London, UK; Brentwood, TN, US; 14 February 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today provides its Interim Management Statement for the quarter ended 31 December 2007.
More Information

Block Listing Six Monthly Return
8 February 2008
London, UK; Brentwood, TN, US: 8 February 2008 - Protherics PLC (“Protherics” or the
“Company”), the international biopharmaceutical company focused on critical care and
cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of a
block listing for the Company’s 6% Unsecured Convertible Loan Notes:
More Information

Start of OncoGel Phase 2b Study in Oesophageal Cancer
24 January 2008
London, UK; Brentwood, TN, US; 24 January 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that the first patient has now been enrolled in a phase 2b study of OncoGel™ in oesophageal cancer. OncoGel™ is a novel locally-administered sustained-release formulation of paclitaxel, an established chemotherapeutic agent for the treatment of solid tumours.
More Information

Start of CytoFab™ Phase 2 Programme in Severe Sepsis
22 January 2008
London, UK; Brentwood, TN, US; 22 January 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that AstraZeneca has treated the first patient in its expanded phase 2 programme of CytoFab™ in severe sepsis, an inflammatory condition resulting from uncontrolled infections.
More Information

Protherics and Advancell start Acadra™ clinical study in B-cell chronic lymphocytic leukaemia
11 January 2008
London, UK; Brentwood, TN, US; 11 January 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, and its co-development partner, Advancell s.l. (“Advancell”), today announce that the first patient has now been enrolled in a recently initiated phase 1/2 clinical study of Acadra™ (acadesine) in B-cell chronic lymphocytic leukaemia (B-CLL).
More information

Notification of Major Interests in Shares
21 December 2007
London, UK; Brentwood, TN, US: 21 December 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that on 20 December 2007, in accordance with the Transparency Obligations Directive, a notification of interest in the ordinary share capital of the Company was received from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group Companies (“AXA”). The notification follows an increase in the Indirect holding of AXA. Details of the interest notified are as follows:
More Information

Protherics announces Interim Results for six months ended 30 September 2007
20 November 2007
London, UK, Brentwood, TN, 20 November 2007 - Protherics PLC (“Protherics” or the “Company”), the biopharmaceutical company focused on critical care and cancer, today announces its unaudited interim results for the six months ended 30 September 2007.
More information

Patient recruitment in phase 2b “DEEP” study in severe pre-eclampsia completed ahead of schedule
20 November 2007
London, UK; Brentwood, TN, US; 20 November 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that the last patient in the phase 2b Digibind® Efficacy Evaluation in Pre-eclampsia (DEEP) study in severe pre-eclampsia, a potentially life-threatening condition of pregnancy, has been enrolled and treated.
More information

Protherics licenses its Covaccine HT adjuvant to Nobilon for influenza vaccine indications
26 September 2007
London, UK and Boxmeer, The Netherlands; 26 September 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, and Nobilon International B.V. (“Nobilon”), part of Organon, the human health care business unit of Akzo Nobel, today announced that Nobilon has licensed Protherics’ CoVaccine HT™ adjuvant for use in pandemic influenza vaccines and seasonal influenza vaccines in elderly people.
More information

Protherics signs ReGel™ licensing agreement with Myungmoon Pharm.
25 September 2007
London, UK; Brentwood, TN, US; 25 September 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that it has signed a licensing agreement with Myungmoon Pharm. Co. Ltd., a Korean pharmaceutical company, granting it the rights to develop anti-inflammatory products using Protherics’ local, sustained release drug delivery system ReGel™.
More information

Board Changes - Update
10 August 2007
London, UK; Brentwood, TN, US: 10 August 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces that Rolf Soderstrom has now commenced as Finance Director of Protherics, following the announcement of his appointment on 26 April 2007.
More information

AGM and Interim Management Statement
26 July 2007
London, UK; Brentwood, TN, US; 26 July 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, provides its Interim Management Statement ahead of the Company’s AGM at midday today.
More information

Prolarix dose selected for phase 2 liver cancer study
12 July 2007
London, UK; Brentwood, TN, US; 12 July 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces the maximum tolerated dose (“MTD”) of Prolarix™ has been determined in a phase 1 study being conducted under the auspices of Cancer Research UK. Prolarix™ is a novel targeted prodrug therapy being developed for the treatment of primary liver cancer (hepatocellular carcinoma) and other selected tumours.
More information

Preliminary results for year ended 31 March 2007
5 June 2007
NeLondon, UK, Brentwood, TN, 5 June 2007 - Protherics PLC, (“Protherics” or the “Company”), the biopharmaceutical company focused on critical care and cancer, today announces its preliminary results for the 12 months ended 31 March 2007.

To access an audio recording of the results presentation please click here.
More information

Notification of Preliminary Results
25 May 2007
London, 25 May 2007: Protherics PLC (“Protherics”), the biopharmaceuticalcompany focused on critical care and cancer, will be announcing its preliminary results for the year ended 31 March 2007, on Tuesday 5 June 2007.
More information

Protherics presents encouraging OncoGel™ phase 2a oesophageal cancer data at leading US conference
22 May 2007
London, UK; Brentwood, TN, US; 22 May 2007 - Protherics PLC (“Protherics” or the“Company”), the international biopharmaceutical company focused on critical care and cancer,announces that positive phase 2a data supporting the development of OncoGel™ inoesophageal cancer were presented yesterday during a poster session at the DigestiveDisease Week (“DDW”) 2007 Conference in Washington, DC. The poster was selected as a“Poster of Distinction,” placing it in the top 10% of all American Gastroenterology Association(AGA) Institute abstracts selected for poster presentation.

Please click here for the a PDF of the OncoGel Poster.
More information

Voraxaze™ Update
22 May 2007
London, UK; Brentwood, TN, US; 22 May 2007 - Protherics PLC (“Protherics” or the“Company”), the international biopharmaceutical company focused on critical care andcancer, today provided an update on its Voraxaze™ marketing applications in the US andEU. Voraxaze™ is an adjunctive therapy for patients with impaired renal function who areexperiencing, or at risk of, toxicity from methotrexate (“MTX”), a widely used anti-canceragent.
More information

Board changes and trading update
26 April 2007
London, UK; Brentwood, TN, US; 26 April 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announces a number of changes to its Board and provides a trading update to the market.
More information

Protherics initiates OncoGel™ phase 1/2 brain cancer study
27 March 2007
London, UK; Brentwood, TN, US; 27 March 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces the enrolment of the first patient in a clinical study to investigate the use of OncoGelTM, a novel formulation of paclitaxel for local administration, as an adjuvant treatment to surgical removal of the tumour in patients with recurrent glioblastoma multiforme (GBM).
More information

Protherics to receive £10 million milestone from AstraZeneca
12 March 2007
London, UK; Brentwood, TN, US; 12 March 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that a £10 million milestone payment from AstraZeneca has been triggered as a result of the successful scale-up of the CytoFab™ manufacturing process to a 600 litre batch size. This milestone will be included in the Company’s results for the financial year ending 31 March 2007 and is expected to be received in April.
More information

Appointment of Non-executive Director
24 January 2007
London, UK; Brentwood, TN, US; 24 January 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, is pleased to announce the appointment of Dr Jacques Gonella as a non-executive director, with effect from today. He will serve on the Company’s audit, nomination and remuneration committees.
More information

Protherics awarded £1m SMARTCymru grant
16 January 2007
Protherics has been granted £1 million through the Welsh Assembly Government’s SMARTCymru programme. The programme is designed to assist Welsh individuals and small and medium-sized businesses to undertake research and development into new technology, products and processes. The grant will be used to support the manufacture of Protherics’ promising anti-sepsis drug CytoFab™, which is being developed in partnership with AstraZeneca.

Dr Andrew Heath, Chief Executive of Protherics, commented: “Protherics is very pleased that the Welsh Assembly Government recognises the potential for CytoFab™ to be a major blockbuster product in the treatment of sepsis. The SMARTCymru grant will assist us to develop our manufacturing processes in Ceredigion and contribute to making what we believe is an important new treatment available to sepsis patients worldwide."


Voraxaze™ Update
11 January 2007
London, UK; Brentwood, TN, US; 11 January 2007 - Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today provides an update on progress with Voraxaze™ in the United States and Europe. Voraxaze™ is an adjunctive therapy for patients experiencing, or at risk of, toxicity from methotrexate (“MTX”), a widely used anti-cancer agent.
More information

Protherics submits DigiFab™ New Drug Submission in Canada
8 January 2007
London, UK; Brentwood, TN, US: 8 January 2007 – Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, today announces that it has submitted a New Drug Submission to the Health Products and Food Branch of Health Canada for DigiFabTM. DigiFabTM is the leading digoxin antidote in the US where it is approved for the treatment of life-threatening or potentially life-threatening digoxin toxicity or overdose.
More information

Completion of MacroMed Acquisition
4 January 2007
London, UK; Brentwood, TN, US; 4 January 2007 - Protherics PLC (“Protherics” or the ”Company”), the international biopharmaceutical company focused on critical care and cancer, announces that its acquisition of MacroMed, Inc., a private US based drug development and manufacturing company, has completed at 4.00 pm GMT (9.00 am MST) today.
More information

Result of Placing and Open Offer
3 January 2007
London, UK; Brentwood, TN, US; 3 January 2007 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, announced on 7 December 2006 the signing of three agreements to expand its development pipeline and the issue of 58,715,544 new Ordinary Shares through a placing for cash and a proposed Placing and Open Offer at an issue price of 65 pence per share, underwritten by Nomura Code Securities Limited and Piper Jaffray Ltd.
More information

2007 News
2006 News Archive
2005 News Archive
2004 News Archive
2003 News Archive
2002 News Archive
2001 News Archive
2000 News Archive